Medicare AdvantageCoverageLow impact
MA08.013, Revakinagene taroretcel-lwey (Encelto®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
A new Medicare Advantage policy MA08.013 has been implemented for Revakinagene taroretcel-lwey (Encelto®), a specialty pharmacy medication. This appears to be a gene therapy treatment that will now have specific coverage guidelines under Medicare Advantage plans.
Action Required
By December 29, 2025: Billing team should review the full policy details at the source URL to understand coverage criteria, prior authorization requirements, and billing procedures for Revakinagene taroretcel-lwey (Encelto®). Update billing system with any specific requirements for this gene therapy medication if your practice administers specialty pharmaceuticals.